Kiora names Keith Lane EVP for clinical, regulatory
Kiora Pharmaceuticals, Inc. (KPRX) appointed Keith J. Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs effective September 8, 2026.
Rhea-AI Filing Summary
Kiora Pharmaceuticals, Inc. (KPRX) appointed Keith J. Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs effective September 8, 2026. Lane brings over 20 years of ophthalmology-focused clinical development and regulatory experience, including leadership at Ora, Inc. and oversight of more than 60 ophthalmic clinical trials.
Under a June 22, 2026 Offer Letter, Lane will receive a $350,000 annual base salary, a $75,000 sign-on bonus, and is eligible for an annual performance bonus targeted at up to 35% of base salary. Subject to Compensation Committee approval under the 2024 Equity Incentive Plan, he will be granted an option to purchase up to 55,000 shares of Kiora common stock, vesting one-third on the first anniversary of the grant and monthly over the following two years. Kiora also furnished a press release announcing the hiring as an exhibit.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
3 items: 5.02, 7.01, 9.01
3 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Annual base salary: $350,000
Sign-on bonus: $75,000
Target performance bonus: 35% of annual base salary
+5 more
8 metrics
Annual base salary
$350,000
Compensation for Keith Lane under the Offer Letter effective September 8, 2026
Sign-on bonus
$75,000
One-time sign-on bonus for Keith Lane
Target performance bonus
35% of annual base salary
Annual performance bonus target for Keith Lane
Stock option grant size
55,000 shares
Option to purchase Kiora common stock for Keith Lane under the 2024 Equity Incentive Plan
Vesting schedule initial cliff
1 year
One-third of option shares vest on the one-year anniversary of the grant date
Additional vesting period
2 years
Remaining option shares vest in equal monthly installments over two years after the first anniversary
Ophthalmic trials overseen
More than 60 trials
Clinical operations and regulatory strategy overseen by Keith Lane at Ora, Inc.
Global Phase 3 pivotal studies
12 studies
Phase 3 trials overseen by Keith Lane that supported NDA and BLA submissions
Key Terms
biologics license application, retinitis pigmentosa, macular edema, inherited retinal disease, +1 more
5 terms
biologics license application regulatory
"supported three new drug application submissions and one biologics license application submission"
A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.
retinitis pigmentosa medical
"KIO-301 for retinitis pigmentosa and other inherited retinal diseases"
Retinitis pigmentosa is a group of inherited disorders that slowly damage the light-sensing cells in the retina, causing progressive loss of peripheral and night vision and often leading to legal blindness. It matters to investors because the condition defines a clear patient population and long-term need for treatments, making clinical trial design, potential market size, and regulatory approval pathways central considerations when valuing companies developing diagnostics or therapies.
macular edema medical
"KIO-104 is being developed for macular edema associated with retinal inflammation"
Macular edema is a buildup of fluid in the macula, the small central part of the eye responsible for sharp, straight-ahead vision, which causes blurred or distorted sight as if looking through a smudged camera lens. For investors it matters because the condition drives demand for treatments, influences clinical trial results and regulatory approvals, and can change a company’s sales and valuation when new drugs or devices prove effective or fail.
inherited retinal disease medical
"across retinal disease, inherited retinal disease, glaucoma, optic neuropathies"
clinical-stage biotechnology company financial
"Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What executive leadership change did KPRX announce on September 8, 2026?
Kiora Pharmaceuticals appointed Keith J. Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs, effective September 8, 2026, to oversee U.S. and global clinical development and registration studies for its ophthalmic pipeline.
What is Keith Lane’s compensation package at Kiora Pharmaceuticals (KPRX)?
Keith Lane will receive a $350,000 annual base salary, a $75,000 sign-on bonus, and is eligible for a performance bonus targeted at up to 35% of his annual base salary, as set out in the Offer Letter effective September 8, 2026.
What equity award will Keith Lane receive from KPRX?
Subject to Compensation Committee approval, Kiora will grant Keith Lane an option to purchase up to 55,000 shares of common stock under the 2024 Equity Incentive Plan, vesting one-third on the first anniversary of grant and then in equal monthly installments over two additional years.
What relevant experience does Keith Lane bring to Kiora Pharmaceuticals (KPRX)?
Keith Lane has over 20 years of ophthalmic drug development and regulatory experience. At Ora, Inc., he oversaw more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies supporting three NDA and one BLA submissions.
How did Kiora Pharmaceuticals (KPRX) communicate Keith Lane’s appointment to the market?
Kiora issued a press release on September 8, 2026 announcing Keith Lane’s hiring. The release is furnished as Exhibit 99.1 and, along with the news, is not deemed filed for purposes of Section 18 of the Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 8, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
| (Commission File Number) | (IRS Employer Identification No.) | ||||
(858 ) 224-9600
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class: | Trading Symbol(s) | Name of each exchange on which registered: | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On September 8, 2026 (the “Effective Date”), Kiora Pharmaceuticals Inc. (the “Company”) appointed Keith Lane as Executive Vice President, Head of Clinical Development and Regulatory Affairs of the Company, effective as of the Effective Date.
Mr. Lane, age 45, previously served as Chief Scientific Officer (“CSO”) for Ora, Inc. (“Ora”), an ophthalmology-focused clinical research organization, from September 2025 to July 2026. Prior to his CSO role, while still at Ora, he served as Senior Vice President and Therapeutic Area Head-Posterior Segment from October 2019 to September 2025, as well as various other roles since joining their company in August 2003. During his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission. His experience spans small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.
In connection with Mr. Lane’s appointment as Executive Vice President, Head of Clinical Development and Regulatory Affairs, the Company entered into an Offer Letter (the “Offer Letter”) with Mr. Lane on June 22, 2026 and effective as of the Effective Date. Pursuant to the Offer Letter, Mr. Lane will receive an annual base salary of $350,000, a sign-on bonus of $75,000, and he is entitled to receive a performance bonus with a target of up to 35% of his annual base salary for the applicable fiscal year. Additionally, subject to the approval of the Compensation Committee of the Company’s Board of Directors and issuance under the Company’s 2024 Equity Incentive Plan, the Company will grant Mr. Lane an option to purchase up to 55,000 shares of the Company’s common stock (the “Option”). The Option will vest with respect to one-third of the underlying shares on the one-year anniversary of the grant date, and thereafter will vest in equal monthly installments over a two-year period.
There is no family relationship between Mr. Lane and any director or executive officer of the Company. There are no transactions between Mr. Lane and the Company that would be required to be reported under Item 404(a) of Regulation S-K under the Securities Exchange Act of 1934, as amended.
The foregoing summary of the material terms of the Offer Letter does not purport to be complete and is subject to, and qualified in its entirety by, the full and complete terms of the Offer Letter, a copy of which is filed with this Current Report on Form 8-K as Exhibit 10.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
On September 8, 2026, the Company issued a press release announcing the hiring of Mr. Lane, a copy of which is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference.
The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| Exhibit Number | Title | |||||||
10.1# | Offer Letter by and between Kiora Pharmaceuticals, Inc. and Keith Lane dated as of June 22, 2026 | |||||||
99.1 | Press Release of Kiora Pharmaceuticals, Inc., dated as of September 8, 2026 | |||||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). | |||||||
# Management contract or compensatory plan or arrangement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| KIORA PHARMACEUTICALS, INC. | ||||||||
| By: | /s/ Melissa Tosca | |||||||
| Melissa Tosca | ||||||||
Chief Financial Officer | ||||||||
| (Principal financial and accounting officer) | ||||||||
| Date: September 8, 2026 | ||||||||
Exhibit 99.1
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
Clinical development executive brings over 20 years of ophthalmology experience supporting U.S. and global clinical trials to support the advancement of Kiora’s pipeline and new asset opportunities
ENCINITAS, CA -- September 8, 2026 -- Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) (“Kiora” or the “Company”) today announced the appointment of Keith J. Lane, MBA, as Executive Vice President of Clinical Development and Regulatory Affairs. Mr. Lane has over 20 years of experience in ophthalmic drug development, clinical development and operations and regulatory strategy across Phase 1 through Phase 4 clinical trials.
“Keith has substantial experience supporting U.S. and global clinical programs across retinal diseases, optic neuropathies and other ophthalmic indications,” said Brian M. Strem, Ph.D., President and Chief Executive Officer of Kiora. “He brings the ability to connect clinical strategy with trial execution, to assess therapeutic activity, support regulatory approval, and generate evidence-driven data to drive physician adoption and payer coverage. Keith has built a vast network of ophthalmic KOLs who can potentially add further value to Kiora’s pipeline. His responsibilities will encompass U.S. and global clinical development and registration studies for our current pipeline, supporting KIO-301 for retinitis pigmentosa and other inherited retinal diseases, as needed by our partners, and helping advance potential future pipeline assets.”
Mr. Lane joins Kiora from Ora, Inc., an ophthalmology-focused clinical research organization, where he most recently served as the Chief Scientific Officer. During his tenure, he oversaw clinical operations and regulatory strategy for more than 60 ophthalmic trials, including 12 global Phase 3 pivotal studies that supported three new drug application submissions and one biologics license application submission. His experience spans small molecules, biologics, gene therapies and cell therapies across retinal disease, inherited retinal disease, glaucoma, optic neuropathies and inflammatory eye conditions.
“I was attracted to Kiora by its science, its team and its strategy of developing small molecules that target novel biological pathways,” Mr. Lane said. “This approach could provide new ways to treat or prevent vision loss caused by progressive degenerative and acute, vision-threatening retinal diseases. Kiora’s commitment to addressing rare and broader-market diseases with limited or no treatment options aligns closely with my personal motivation to help bring meaningful therapies to patients in need.”
Mr. Lane earned an MBA in health sector management, with honors, from Boston University’s Questrom School of Business and a Bachelor of Science from Bates College.
About Kiora Pharmaceuticals
Kiora Pharmaceuticals is a clinical-stage biotechnology company developing therapies for retinal disease. The Company targets critical pathways underlying retinal diseases using small molecules designed to slow, stop or restore vision loss. KIO-301 is being developed initially for retinitis pigmentosa, with potential expansion into choroideremia and Stargardt disease. KIO-104 is being developed for macular edema associated with retinal inflammation.
In addition to news releases and SEC filings, Kiora posts information on its website, www.kiorapharma.com, and social media accounts that could be relevant to investors. Investors are encouraged to follow Kiora on X and LinkedIn and subscribe to email alerts.
Contacts
Investors
Investors@kiorapharma.com
Media
Susan Sharpe
Linnden Communications
susan@linndencom.com